Trump AI Summit Targets Hardware as Key to US Supremacy
Tesla and Samsung: Elon Musk's EV maker agreed a $16.5 billion chipmaking pact with Samsung, which will see the Korean company dedicate its production in an upcoming Texas fab to making the brains of future Tesla self-driving systems.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
Food distributor Sysco beats quarterly expectations as US demand improves
-Packaged and fresh food distributor Sysco beat analysts' estimates for fourth-quarter revenue and profit on Tuesday, helped by improvement in its U.S. operations. The company, which supplies to chains such as KFC and Subway, has been grappling with an uneven recovery in restaurant industry traffic as looming economic uncertainties prompted consumers to increasingly cook meals at home. Sysco's U.S. foodservice segment, its largest business, posted sales of $14.76 billion during the quarter ended June 28, up 2.4% over the year earlier. The segment had seen a 0.7% increase in the preceding quarter. The company is also trying to cut costs through measures such as renegotiation of supplier contracts to procure raw materials at lower prices. To lower shipping expenses, it has introduced programs such as "Sysco-to-go", which requires customers to pick up orders directly from its stores. On an adjusted basis, it earned $1.48 per share during the fourth quarter, beating analysts' average estimate of $1.39 per share, according to data compiled by LSEG. Sysco's total sales rose 2.8% to $21.14 billion, also ahead of the estimate of $21.03 billion. The Houston, Texas-based company forecast fiscal 2026 adjusted earnings per share to be between $4.50 and $4.60. Analysts were expecting a profit of $4.67 per share. The company's shares were down 3% in early trading. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
12 minutes ago
- Yahoo
Tesla's Affordable EV Is So Much Less Than "Just A Model Y"
Tesla's Affordable EV Is So Much Less Than "Just A Model Y" originally appeared on Autoblog. Chinese Leak Reveals Significant Changes Back in February, Tesla began promising new Model Y variants, and since then, the Model Y L has been revealed as a bigger six-seater for China. There have also been rumors of a more luxurious long-wheelbase variant with captain's chairs after a white-hat hacker found evidence of such a thing in Model Y firmware. As for the long-awaited cheaper Model Y, that was delayed in April, and thanks to a video from China, it seems that the automaker has been working quietly in the background. Don't worry if you don't speak Mandarin - Not A Tesla App reports what to expect. Several Changes Inside And Out At the front of the car, the front fascia and headlight assembly have been revised, with the lightbar apparently disappearing and the headlight on either side thereof moving upward, much like the pre-Juniper Model Y. The remarkably strong glass roof that has appeared on every Tesla to date is gone, and at the back, the reflectors in the tailgate are just that - no fancy five-foot lightbar like the current Model Y. Still, a front-facing camera indicates it'll have access to the same semi-autonomous driving features as other Teslas, so it won't be completely decontented. Inside, the multimedia experience will be slightly diminished; there is no rear infotainment display, and the A-pillars have lost their speakers. Also missing are coat hooks and a rear parcel shelf, while the center console has been updated to move phone chargers below the central touchscreen, where there is now a gap between the dash and center console. Finally, the seat bolsters glimpsed beneath the seat covers appear to have been finished in a textile rather than synthetic leather, as is the case with Mexico's Model 3 (the same material is likely for the headliner). Although unconfirmed at this stage, we can expect features like heated and ventilated seats and a heated steering wheel to disappear, too. "Just A Model Y," But It Could Help Turn Tesla's Fortunes Around View the 3 images of this gallery on the original article Tesla recently released its Q2 earnings report for 2025, and the news was not good, with a sharp decline in profits and no promise of improvements from CEO Elon Musk, who said to expect a "few rough quarters." Still, although Musk says it's nothing special - "It's just a Model Y" - Tesla said volume production of "a more affordable model" would occur in the second half of the year, and that should help boost sales at least somewhat. This sighting confirms the car will be as cheap as possible, but whether it will cost much less than $40,000 remains to be seen. Without the $7,500 Federal Tax credit that expires at the end of September, the current cheapest Model Y (Long Range Rear-Wheel Drive) starts at $44,990, so Tesla may resort to further incentives in an effort to stave off ever-increasing rival competition amid weak growth in EV Affordable EV Is So Much Less Than "Just A Model Y" first appeared on Autoblog on Jul 29, 2025 This story was originally reported by Autoblog on Jul 29, 2025, where it first appeared.
Business Wire
13 minutes ago
- Business Wire
Paige and Oncoclínicas Strengthen Leadership in AI-Driven Cancer Diagnostics Across Brazil
NEW YORK & SíO PAULO--(BUSINESS WIRE)--Paige, a leader in next-generation AI technology, announced the continued and expanded use of its innovative AI-assisted diagnostic applications by long-time customer, Oncoclínicas&Co (Oncoclínicas), the largest private group of cancer care in Latin America. With a commitment to enhancing diagnostic capabilities and improving patient safety, Oncoclínicas has utilized Paige's technology across prostate and breast cancer diagnosis, supporting its commitment to advancing pathology standards throughout Brazil. Oncoclínicas employs a rigorous approach where all digitized prostate and breast cancer biopsy whole-slide images are analyzed by pathologists using AI as an adjunct diagnostic tool. This process provides extra layers of patient safety, enhancing both sensitivity and efficiency for the pathologists using the technology. Since August 2021, Oncoclínicas has utilized AI to support the review of over 23,000 prostate and breast biopsies. These results demonstrate the scale and commitment of Oncoclínicas to AI integration in their diagnostic workflow, which has led to Oncoclínicas' achieving: Faster second reader sign-out for senior pathologists using FullFocus™ and AI support. 1 Enhanced detection rates, including the identification of approximately .5% of precursor non-obligatory breast lesions that were not initially detected by pathologists. 1 Improved diagnostic consistency and efficiency through the use of Paige Prostate and Paige Breast AI Suites. 1 Dr. Leonard Medeiros da Silva, pathologist at OC Medicina de Precisão, an integrated laboratory of Oncoclínicas&Co dedicated to pathological anatomy, genetic testing and Big Data, reports a positive experience with Paige Prostate. "It aligns with Oncoclínicas published data showing nearly 100% sensitivity and 93% specificity,' he notes. 'The specialist also commends the technology's effectiveness in both cancer detection and accurate Gleason score determination.' 'We are proud to support Oncoclínicas in their mission to offer cutting-edge cancer diagnostic solutions,' said Dr. Juan Retamero, Medical Vice President at Paige. 'Their success in implementing AI technology is a testament to their dedication to clinical excellence and their forward-thinking approach to pathology. Our long-term partnership underscores Paige's commitment to providing access to high-quality AI technology globally, helping pathologists provide better diagnoses for their patients.' 'Over the past few months, I've had the opportunity to witness how the integration of digital pathology, biomarkers, AI, and genomics is accelerating the advancement of precision medicine, and, more importantly, improving patients' quality of life and offering new hope in the fight against cancer,' said Rodrigo Alvarenga, Operations Executive at Oncoclínicas&Co. 'At both the 2025 USCAP in Boston and ASCO in Chicago, it became clear that precision medicine is no longer a distant goal, but a present-day reality that can expand access to advanced technologies and enable more cost-effective care. We've reached an exciting point of no return, the convergence of AI, pathology, and genomics is not only transforming cancer care but is also critical to the long-term sustainability of our healthcare systems.' In Brazil, FullFocus™ and all AI assisted diagnostic applications such as the Paige Prostate Suite and the Paige Breast Suite are for Research Use Only. Not for use in diagnostic procedures. 1 Figures are based on independent clinical research conducted by Oncoclínicas&Co. Finding an average of 12,000 breast biopsies and surgical specimens were analyzed in 2024. The Paige Breast Suite as a second reader detected 55 non-obligatory precursor breast lesions that were not initially detected by pathologists. Additionally, after utilizing FullFocus™ with the Paige Prostate Suite, the average time to read a slide and complete a report reduced to one minute and 10 seconds. About Oncoclínicas&Co Oncoclínicas&Co is the largest group dedicated to cancer treatment in Latin America, with a highly specialized and innovative model focused on the oncology journey. With a medical staff of over 2,900 oncology specialists, the company operates in 40 Brazilian cities, totaling more than 140 units. Focused on research, technology, and innovation, the group has conducted approximately 682,000 treatments in the past 12 months. Oncoclínicas follows international standards of excellence, integrating outpatient clinics with high-complexity cancer centers, enhancing treatment through precision medicine and genomics. As the exclusive partner of the Dana-Farber Cancer Institute in Brazil, affiliated with Harvard Medical School, it has acquired Boston Lighthouse Innovation (USA) and holds a stake in MedSir (Spain). It is also part of the IDIVERSA index of B3, reinforcing its commitment to diversity. With the goal of expanding its global mission to overcome cancer, Oncoclínicas has entered Saudi Arabia through a joint venture with the Al Faisaliah Group, bringing its oncology expertise to a new continent. Learn more at: About Paige Paige is pushing the boundaries of AI to solve cancer's most critical issues, revolutionizing cancer care with next-generation technology. By leveraging exclusive access to millions of digitized pathology slides, clinical reports, and genomic data, Paige gains a holistic understanding of cancer, encompassing diverse factors such as gender, race, ethnicity, and geographical regions. This comprehensive data enables Paige to create advanced AI solutions that redefine cancer detection, diagnosis, and treatment. With a unique, intricate understanding of tissue, Paige sets new standards in precision diagnostics, earning the distinction of being the first FDA-cleared AI application in pathology. Paige has also developed the first million-slide foundation model for cancer, continuing to lead the way in uncovering novel insights and transforming them into life-changing products. For more information, visit
